New developments in immunosuppressive therapy for heart transplantation

Bibliography

• Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967;41(48):1271-4
   PubMedGoogle Scholar
• Taylor DO, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report, 2008. J Heart Lung Transplant 2008;27(9):943-56
   PubMed Web of Science ®Google Scholar
• Eisen HJ. Immunosuppression on the horizon. Heart Fail Clin 2007;3(1):43-9
   PubMedGoogle Scholar
• Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 2006;26(3):201-10
   PubMed Web of Science ®Google Scholar
• Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant 2002;2(10):898-903
   PubMed Web of Science ®Google Scholar
• Mankidy B, Kesavan RB, Silay YS, et al. Emerging drugs in lung transplantation. Expert Opin Emerg Drugs 2007;12(1):61-73
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996;15(5):435-42
   PubMed Web of Science ®Google Scholar
• Chien NC, Lin FL, Chou NK, et al. Rabbit antithymocyte globulin induction immunosuppression in heart transplantation. Transplant Proc 2000;32(7):2380-2
   PubMed Web of Science ®Google Scholar
• Lavee J, Bar-Zohar D, Har-Zahav Y, et al. Immunosuppression induction with rabbit antithymocyte globulin in heart transplantation patients: 6-year experience at the Sheba Medical Center. Transplant Proc 2000;32(4):737-9
   PubMed Web of Science ®Google Scholar
• Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 2003;75(3):354-8
   PubMed Web of Science ®Google Scholar
• Goland S, Czer LS, Coleman B, et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates. J Heart Lung Transplant 2008;27(10):1115-21
   PubMed Web of Science ®Google Scholar
• Starnes VA, Oyer PE, Stinson EB, et al. Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 1989;80(5 Pt 2):III79-83
   PubMedGoogle Scholar
• Barr ML, Sanchez JA, Seche LA, et al. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990;82(5 Suppl):IV291-4
   PubMedGoogle Scholar
• Van Gelder T, Daane CR, Vaessen LM, et al. In vitro and in vivo effects of BT 563, an anti-interleukin-2 receptor monoclonal antibody. Transpl Int 1994;7(Suppl 1):S556-8
   PubMedGoogle Scholar
• Available from: www.clinicaltrials.gov [Cited 2 October 2008]
   Google Scholar
• Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003;76(1):120-9
   PubMed Web of Science ®Google Scholar
• Silveira FP, Marcos A, Kwak EJ, et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect 2006;53(4):241-7
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004;136(4):754-60
   PubMed Web of Science ®Google Scholar
• Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation–efficacy and safety at five years. Am J Transplant 2005;5(6):1347-53
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, Pirsch JDH, Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3(6):722-30
   PubMed Web of Science ®Google Scholar
• Vathsala A, Ona ET, Tan SY, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005;80(6):765-74
   PubMed Web of Science ®Google Scholar
• Pham SM, Jimenez J, Bednar BM. Campath in clinical heart transplantation. J Heart Lung Transplant 2006;25:S126
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction: long-term results. Am J Transplant 2006;6(2):331-9
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/sezary syndrome. Blood 2004;104(3):655-8
   PubMed Web of Science ®Google Scholar
• Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006;81(11):1542-8
   PubMed Web of Science ®Google Scholar
• Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005;24(9):1297-304
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352(26):2705-13
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4(2):222-30
   PubMed Web of Science ®Google Scholar
• Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 2005;24(4):392-400
   PubMed Web of Science ®Google Scholar
• Baran DA. Induction therapy in cardiac transplantation: when and why? Heart Fail Clin 2007;3(1):31-41
   PubMedGoogle Scholar
• Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000;20(2):108-25
   PubMed Web of Science ®Google Scholar
• Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351(26):2715-29
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005;353(16):1711-23
   PubMed Web of Science ®Google Scholar
• Felkel TO, Smith AL, Reichenspurner HC, et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant 2002;21(5):530-9
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA, Park MH, et al. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. Transplant Proc 2004;36(10):3152-5
   PubMed Web of Science ®Google Scholar
• Keogh A, Macdonald P, Harvison A, et al. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: two views of the steroid question. J Heart Lung Transplant 1992;11(2 Pt 2):421-7
   PubMed Web of Science ®Google Scholar
• Rosenbaum DH, Adams BC, Mitchell JD, et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg 2006;82(2):637-44
   PubMed Web of Science ®Google Scholar
• O'Connell JB, Bristow MR, Rasmussen LG, et al. Cardiac allograft function with corticosteroid-free maintenance immunosuppression. Circulation 1990;82(5 Suppl):IV318-21
   PubMedGoogle Scholar
• Olivari MT, Jessen ME, Baldwin BJ, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995;14(1 Pt 1):127-35
   PubMed Web of Science ®Google Scholar
• Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol 2008;52(8):587-98
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Matsuno N, Hirano T, et al. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level. Transplant Proc 2008;40(7):2240-2
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006;6(6):1377-86
   PubMed Web of Science ®Google Scholar
• Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients: a large European trial. Am J Transplant 2006;6(6):1387-97
   PubMed Web of Science ®Google Scholar
• Elion GB. The purine path to chemotherapy. Science 1989;244(4900):41-7
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005;24(5):517-25
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31(5):335-40
   PubMed Web of Science ®Google Scholar
• Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004;100(4):657-66
   PubMed Web of Science ®Google Scholar
• Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110(17):2694-700
   PubMed Web of Science ®Google Scholar
• Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001;72(5):851-5
   PubMed Web of Science ®Google Scholar
• Gustafsson F, Ross HJ. Proliferation signal inhibitors in cardiac transplantation. Curr Opin Cardiol 2007;22(2):111-6
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349(9):847-58
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998;66(4):507-15
   PubMed Web of Science ®Google Scholar
• Manito N, Kaplinsky EJ, Bernat R, et al. Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant 2004;23(6):780-2
   PubMed Web of Science ®Google Scholar
• Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant 2005;5(6):1392-6
   PubMed Web of Science ®Google Scholar
• Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible sirolimus-associated pneumonitis after heart transplantation. J Heart Lung Transplant 2006;25(2):241-4
   PubMed Web of Science ®Google Scholar
• Exposito V, de Prada JA, Gomez-Roman JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008;27(7):797-800
   PubMed Web of Science ®Google Scholar
• Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006;6(5 Pt 1):986-92
   PubMed Web of Science ®Google Scholar
• Kushwaha SS, Khalpey Z, Frantz RP, et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005;24(12):2129-36
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Nissen SE. Certican (everolimus) for the proposed indication of prophylaxis of rejection in heart transplantation; report from the Cardiovascular and Renal Drugs Advisory Committee, US food and drug administration, November 16, 2005, Rockville, MD. Circulation 2006;113:e394-e5
   PubMed Web of Science ®Google Scholar
• Lehmkuhl H, Hetzer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 2005;24(4 Suppl):S201-5; discussion S10-1
   PubMed Web of Science ®Google Scholar
• Lyster H, Panicker G, Leaver N, Banner NR. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc 2004;36(10):3167-70
   PubMed Web of Science ®Google Scholar
• Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. J Heart Lung Transplant 2007;26(6):557-64
   PubMed Web of Science ®Google Scholar
• Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006;25(3):283-8
   PubMed Web of Science ®Google Scholar
• Frist WH, Biggs VJ. Chronic myelogenous leukemia after lymphoid irradiation and heart transplantation. Ann Thorac Surg 1994;57(1):214-6
   PubMed Web of Science ®Google Scholar
• Ross HJ, Gullestad L, Pak J, et al. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. J Heart Lung Transplant 1997;16(2):179-89
   PubMed Web of Science ®Google Scholar
• Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006;25(2):153-9
   PubMed Web of Science ®Google Scholar
• Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22(1):58-69
   PubMed Web of Science ®Google Scholar
• Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24(11):1710-20
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 Pt 1):859-66
   PubMed Web of Science ®Google Scholar
• Ramzy D, Rao V, Brahm J, et al. Cardiac allograft vasculopathy: a review. Can J Surg 2005;48(4):319-27
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998;17(8):744-53
   PubMed Web of Science ®Google Scholar
• Julius BK, Attenhofer Jost CH, Sutsch G, et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation 2000;69(5):847-53
   PubMed Web of Science ®Google Scholar
• Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003;107(1):93-7
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333(10):621-7
   PubMed Web of Science ®Google Scholar
• Keogh A, Macdonald P, Kaan A, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19(6):529-37
   PubMed Web of Science ®Google Scholar
• Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989;139(3):550-7
   PubMed Web of Science ®Google Scholar
• Weis M, Pehlivanli S, Meiser BM, et al. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001;38(3):814-8
   PubMed Web of Science ®Google Scholar
• Akhlaghi F, Ashley J, Keogh A, Brown K. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Ther Drug Monit 1999;21(1):8-16
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7(6):687-92
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6(12):1399-402
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA. Statins in solid organ transplantation: is there an immunosuppressive effect? Am J Transplant 2004;4(7):1013-8
   PubMed Web of Science ®Google Scholar
• Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993;328(3):164-70
   PubMed Web of Science ®Google Scholar
• Steinhauff S, Pehlivanli S, Bakovic-Alt R, et al. Beneficial effects of quinaprilat on coronary vasomotor function, endothelial oxidative stress, and endothelin activation after human heart transplantation. Transplantation 2004;77(12):1859-65
   PubMed Web of Science ®Google Scholar
• Bae JH, Rihal CS, Edwards BS, et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006;82(8):1108-11
   PubMed Web of Science ®Google Scholar
• Erinc K, Yamani MH, Starling RC, et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant 2005;24(8):1033-8
   PubMed Web of Science ®Google Scholar
• Mehra MR, Ventura HO, Smart FW, et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 1995;75(12):853-4
   PubMed Web of Science ®Google Scholar
• Pethig K, Hornig B, Bara C, et al. Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound. J Int Med Res 2008;36(5):1022-31
   PubMed Web of Science ®Google Scholar
• Lim DS, Mooradian SJ, Goldberg CS, et al. Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. Am J Cardiol 2004;94(6):828-31
   PubMed Web of Science ®Google Scholar
• Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002;359(9312):1108-13
   PubMed Web of Science ®Google Scholar
• Iwanaga K, Hasegawa T, Hultquist DE, et al. Riboflavin-mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation. Transplantation 2007;83(6):747-53
   PubMed Web of Science ®Google Scholar
• Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004;78(4):591-8
   PubMed Web of Science ®Google Scholar
• Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108(1):48-53
   PubMed Web of Science ®Google Scholar
• Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 2007;116(23):2726-33
   PubMed Web of Science ®Google Scholar
• Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008;117(16):2131-41
   PubMed Web of Science ®Google Scholar
• Salgar SK, Yang D, Ruiz P, et al. Viral interleukin-10-engineered autologous hematopoietic stem cell therapy: a novel gene therapy approach to prevent graft rejection. Hum Gene Ther 2004;15(2):131-44
   PubMed Web of Science ®Google Scholar
• Minami E, Laflamme MA, Saffitz JE, Murry CE. Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation 2005;112(19):2951-8
   PubMed Web of Science ®Google Scholar
• Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006;7(6):652-62
   PubMed Web of Science ®Google Scholar
• Isobe M, Kosuge H, Suzuki J. T cell co-stimulation in the development of cardiac allograft vasculopathy: potential targets for therapeutic interventions. Arterioscler Thromb Vasc Biol 2006;26(7):1447-56
   PubMed Web of Science ®Google Scholar
• Newell KA, Larsen CP, Kirk AD. Transplant tolerance: converging on a moving target. Transplantation 2006;81(1):1-6
   PubMed Web of Science ®Google Scholar
• Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc 2006;117:199-211
   PubMedGoogle Scholar
• Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003;3(6):653-64
   PubMed Web of Science ®Google Scholar
• Olsen SL, Wagoner LE, Hammond EH, et al. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations. J Heart Lung Transplant 1993;12(2):S135-42
   PubMed Web of Science ®Google Scholar
• Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989;8(6):430-43
   PubMedGoogle Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345(10):747-55
   PubMed Web of Science ®Google Scholar
• Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15(12):3256-62
   PubMed Web of Science ®Google Scholar
• Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998;66(6):800-5
   PubMed Web of Science ®Google Scholar
• De Marco T, Damon LE, Colombe B, et al. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997;16(3):360-5
   PubMed Web of Science ®Google Scholar
• Pradhan M, Raffaelli RM, Lind C, et al. Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis. Pediatr Transplant 2008;12(6):711-6
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359(3):242-51
   PubMed Web of Science ®Google Scholar
• Keown PA. Use of cyclosporine microemulsion (Neoral) in de novo and stable renal transplantation: clinical impact, pharmacokinetic consequences and economic benefits. Canadian and International Neoral Study Groups. Transplant Proc 1996;28(4):2147-50
   PubMed Web of Science ®Google Scholar
• White M, Pelletier GB, Tan A, et al. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. J Heart Lung Transplant 1997;16(8):787-94
   PubMed Web of Science ®Google Scholar
• Yabu JM, Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 2007;27(4):479-86
   PubMed Web of Science ®Google Scholar
• Vincenti F. Chronic induction. What's new in the pipeline. Contrib Nephrol 2005;146:22-9
   PubMed Web of Science ®Google Scholar
• Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol 2001;19(9):819-22
   PubMed Web of Science ®Google Scholar
• Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169(950):1042-9
   PubMed Web of Science ®Google Scholar
• Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212
   PubMed Web of Science ®Google Scholar
• Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004;77(5):769-76
   PubMed Web of Science ®Google Scholar
• First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J 2004;45(6):1127-31
   PubMed Web of Science ®Google Scholar
• Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005;37(2):1211-3
   PubMed Web of Science ®Google Scholar
• Tedesco Silva H Jr, Pinheiro Machado P, Rosso Felipe C, et al. Immunotherapy for de novo renal transplantation: what's in the pipeline? Drugs 2006;66(13):1665-84
   PubMed Web of Science ®Google Scholar
• Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24(9):645-63
   PubMed Web of Science ®Google Scholar
• Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4(2):231-6
   PubMed Web of Science ®Google Scholar
• Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004;4(2):237-43
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006;25(8):935-41
   PubMed Web of Science ®Google Scholar
• Kunzendorf U, Ziegler E, Kabelitz D. FTY720–the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 2004;19(7):1677-81
   PubMed Web of Science ®Google Scholar
• Pan S, Mi Y, Pally C, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 2006;13(11):1227-34
   PubMed Web of Science ®Google Scholar
• Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006;6(12):2912-21
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006;82(12):1689-97
   PubMed Web of Science ®Google Scholar
• Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008;75(10):1893-900
   PubMed Web of Science ®Google Scholar
• Shimizu H, Takahashi M, Kaneko T, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005;111(2):222-9
   PubMed Web of Science ®Google Scholar
• Bilolo KK, Ouyang J, Wang X, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 2003;75(11):1881-7
   PubMed Web of Science ®Google Scholar
• Birsan T, Dambrin C, Klupp J, et al. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl Immunol 2003;11(2):163-7
   PubMed Web of Science ®Google Scholar
• Savikko J, Von Willebrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003;76(3):455-8; discussion 71-3
   PubMed Web of Science ®Google Scholar
• Waldman WJ, Knight DA, Blinder L, et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999;42(5-6):412-8
   PubMed Web of Science ®Google Scholar
• Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007;20(11):962-9
   PubMed Web of Science ®Google Scholar
• Zeng H, Waldman WJ, Yin DP, et al. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation 2005;79(1):17-22
   PubMed Web of Science ®Google Scholar
• Qi S, Zhu S, Xu D, et al. Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. Transplantation 2003;75(8):1124-8
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, van Hooff JP, Klinger M, et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 2004;78(1):9-14
   PubMed Web of Science ®Google Scholar
• Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004;10(11):532-41
   PubMed Web of Science ®Google Scholar
• Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosuppression. Expert Opin Ther Targets 2004;8(6):613-29
   PubMed Web of Science ®Google Scholar
• Saemann MD, Zeyda M, Stulnig TM, et al. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int 2004;17(9):481-9
   PubMed Web of Science ®Google Scholar
• Papageorgiou AC, Wikman LE. Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol Sci 2004;25(11):558-62
   PubMed Web of Science ®Google Scholar
• Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004;4(1):51-7
   PubMed Web of Science ®Google Scholar
• Rousvoal G, Si MS, Lau M, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006;19(12):1014-21
   PubMed Web of Science ®Google Scholar
• Busque S, Leventhal JR, Brennan D. CP-690,550, a JAK3 inhibitor, in de novo kidney transplant recipients: 6-month results of a phase 2 trial. Am J Transplant 2007;7(Suppl 2):304
   Google Scholar
• Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J 2003;376(Pt 3):545-52
   PubMed Web of Science ®Google Scholar
• Slade AV, Hijazi Y, Wagner J. NVP-AEB071: pharmacokinetics and pharmacodynamic activity of a novel T-cell activation inhibitor under multiple-dose conditions [abstract]. Am J Transplant 2006;6:198
   Google Scholar
• Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342(9):605-12
   PubMed Web of Science ®Google Scholar
• Aspeslet L, Freitag D, Trepanier D, et al. ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc 2001;33(1-2):1048-51
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005;5(3):443-53
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353(8):770-81
   PubMed Web of Science ®Google Scholar
• Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant 2006;6(1):27-36
   PubMed Web of Science ®Google Scholar
• Nakakura EK, Shorthouse RA, Zheng B, et al. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation 1996;62(5):547-52
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Alefacept: a safety profile. Expert Opin Drug Saf 2005;4(6):975-85
   PubMedGoogle Scholar
• Vincenti F, Kirk AD. What's next in the pipeline? Am J Transplant 2008;8(10):1972-81
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101(4):1530-4
   PubMed Web of Science ®Google Scholar
• Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics 2008;9(5):585-96
   PubMed Web of Science ®Google Scholar